How to Apply to DBV Technologies

9 min read Last updated April 20, 2026 8 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • DBV Technologies is a struggling clinical-stage French biotech in active turnaround under CEO Daniel Tassé (since March 2024), with two prior FDA rejections of Viaskin Peanut and a workforce reduced by approximately 70% in 2024.
  • The company operates two separate careers portals — French for Châtillon HQ and English for Basking Ridge NJ — and applications must be tailored in language, format, and cultural register to the matching geography.
  • Native or near-native French (C1+) is effectively required for most Châtillon HQ roles, while Basking Ridge roles operate in English with occasional French collaboration.
  • Interview loops are technically rigorous, transparent about company challenges, and reward candidates who have done substantive research on the regulatory history and strategic review.
  • Compensation is competitive within the Paris biotech market but materially below US biotech benchmarks for equivalent roles in Basking Ridge — equity upside depends entirely on a successful Viaskin Peanut path forward.
  • DBV is a high-conviction, high-risk employer best suited to candidates with deep domain expertise, turnaround tolerance, and genuine mission alignment with pediatric food allergy treatment.
  • Hiring volume in 2026 is low and selective — most open roles are critical backfills or strategic hires rather than growth headcount, and candidates should temper expectations about response times and process speed.

About DBV Technologies

DBV Technologies SA (EPA:DBV, NASDAQ:DBVT) is a clinical-stage French biotechnology company founded in 2002 and headquartered in Châtillon, a southern suburb of Paris in the Île-de-France region. The company has built its identity around a single ambitious bet: epicutaneous immunotherapy (EPIT), a patch-based platform that delivers allergens through intact skin to gradually desensitize patients with severe food allergies. Its flagship product candidate, Viaskin Peanut, is designed to treat peanut allergy in children, a condition that affects roughly 2% of children in developed countries and has historically had no approved pediatric patch-based therapy. The candid reality in 2026 is that DBV is a company in the middle of an extended fight for survival. Viaskin Peanut has been rejected by the U.S. Food and Drug Administration twice — first in 2020 over patch adhesion and study design concerns, and again in 2024 after additional regulatory feedback required further trial work. The 2024 readout of the Phase 3 ENABLE study did not deliver the clean win management had hoped for, triggering a strategic review and a workforce reduction estimated at roughly 70% of headcount across global operations. Today the company employs approximately 150 people across four sites: the Châtillon HQ near Paris, U.S. operations in Basking Ridge, New Jersey, a small German presence in Düsseldorf, and a Tokyo office supporting Japanese regulatory engagement. Daniel Tassé took over as CEO in March 2024, brought in with a mandate to stabilize finances, refocus the pipeline, and engineer a credible regulatory path for Viaskin Peanut. The company competes in a crowded landscape that includes Nestlé Health Science's Palforzia (acquired from Aimmune Therapeutics) and Stallergenes Greer's allergy immunotherapy portfolio, both of which have either commercial approval or deeper resources. DBV's differentiation rests on the patch delivery mechanism, which avoids the oral dosing burdens of competitors but has introduced its own technical and regulatory challenges. For job seekers, DBV represents a high-conviction, high-risk environment: meaningful scientific work on a genuine unmet medical need, paired with very real funding, regulatory, and viability questions that any candidate should weigh seriously before joining. The company's small size and concentrated focus mean that individual contributors carry visible weight on programs that would be diluted across hundreds of people at a larger pharma. That visibility cuts both ways: strong work is noticed quickly by senior leadership, and weak work has nowhere to hide. Candidates who thrive at DBV tend to share three traits — deep technical mastery in a single domain, comfort working across French and English business cultures, and an emotional stake in the underlying mission of giving allergy patients a treatment option they currently lack.

Application Process

  1. 1
    Identify the right portal first: DBV operates two distinct careers sites

    Identify the right portal first: DBV operates two distinct careers sites — a French-language portal for Châtillon HQ and EU roles, and an English-language portal for Basking Ridge NJ and US-based positions. Apply on the portal that matches the job location, not both.

  2. 2
    Tailor your CV format to the geography

    Tailor your CV format to the geography. For Châtillon roles submit a French CV (2 pages, with photo optional, and including the standard French sections: Formation, Expérience Professionnelle, Compétences, Langues). For US roles submit a standard 1-2 page English resume with no photo.

  3. 3
    Write a cover letter

    Write a cover letter — it still matters in French biotech hiring culture. For HQ roles, a French lettre de motivation is expected even when not strictly required by the form. For US roles, a concise English cover letter is recommended for scientific and senior positions.

  4. 4
    Apply within 7-14 days of posting

    Apply within 7-14 days of posting. DBV's reduced HR capacity post-2024 layoffs means active reqs often close quickly once a strong shortlist is assembled, and reposted roles indicate the prior candidate fell through rather than fresh openings.

  5. 5
    Expect a recruiter screen within 2-3 weeks for active roles

    Expect a recruiter screen within 2-3 weeks for active roles. The first conversation is typically 30 minutes with HR (in French for Châtillon, English for Basking Ridge), focused on motivation, salary expectations, and authorization to work in the relevant jurisdiction.

  6. 6
    Prepare for a multi-stage technical loop: hiring manager interview, then 2-3 fun

    Prepare for a multi-stage technical loop: hiring manager interview, then 2-3 functional interviews with future peers and cross-functional stakeholders, and a final round with a department head or executive. Total elapsed time from application to offer typically runs 6-10 weeks.

  7. 7
    For scientific and clinical roles, expect a technical presentation or case study

    For scientific and clinical roles, expect a technical presentation or case study — often a 30-45 minute talk on a prior project, followed by deep questions on methodology, data interpretation, and regulatory strategy.

  8. 8
    Reference checks are taken seriously

    Reference checks are taken seriously. DBV's small size and the close-knit Paris biotech community mean back-channel reference conversations are common; assume any former manager or collaborator may be contacted informally before the offer.

Resume Tips for DBV Technologies

recommended

Lead with regulated-industry experience

Lead with regulated-industry experience. DBV is a clinical-stage biotech operating under FDA, EMA, and PMDA scrutiny — surface every GxP, ICH, and 21 CFR Part 11 touchpoint you have, with specific protocols and submission types named.

recommended

Quantify clinical and CMC contributions

Quantify clinical and CMC contributions. Use specific numbers: patients enrolled, sites managed, IND/CTA sections authored, batches released, deviations resolved. Vague phrases like 'supported clinical operations' will not survive a recruiter screen.

recommended

Name the immunotherapy or allergy domain explicitly if you have it

Name the immunotherapy or allergy domain explicitly if you have it. Experience with EPIT, OIT (oral immunotherapy), SLIT (sublingual), allergen extracts, or biologic patches will move your CV to the top of the pile.

recommended

For Châtillon roles, list French language proficiency on the CV with the CEFR le

For Châtillon roles, list French language proficiency on the CV with the CEFR level (B2, C1, C2). Native or C1+ French is effectively required for HQ-based roles outside of select scientific functions.

recommended

Highlight cross-Atlantic collaboration experience

Highlight cross-Atlantic collaboration experience. DBV's operating model spans Paris, NJ, Düsseldorf, and Tokyo — candidates who have worked across European and US regulatory or clinical contexts have a real edge.

recommended

Be honest about gaps and pivots

Be honest about gaps and pivots. Given DBV's own restructuring history, the hiring team is sympathetic to candidates from companies that have downsized or pivoted, but only if your CV tells that story clearly rather than hiding it.

recommended

Include peer-reviewed publications and conference posters for R&D and clinical r

Include peer-reviewed publications and conference posters for R&D and clinical roles. The scientific leadership at DBV reads the literature; relevant publications signal that you operate at their level.

recommended

Skip the corporate jargon

Skip the corporate jargon. A French biotech HR team and a New Jersey clinical operations director will both reward plain, specific language over consulting-deck buzzwords.

ATS System: Custom French and US careers portals (no third-party ATS branding visible)

DBV Technologies operates two separate self-hosted careers portals rather than a single third-party ATS like Workday or Greenhouse. The French portal serves Châtillon HQ and other EU roles in French, while the US portal serves Basking Ridge NJ and other US roles in English. Both portals require account creation, accept PDF and Word resume uploads, and present custom application forms tailored to each jurisdiction's legal disclosure requirements (RGPD consent for EU, EEO self-identification for US).

  • Create separate accounts on the French and US portals if applying to roles in both regions — they do not share candidate data.
  • Submit your CV as a clean PDF with selectable text. The custom portals likely use lightweight parsing, so avoid graphics-heavy templates, multi-column layouts, or text rendered as images.
  • Fill out every form field rather than relying on resume parsing alone. Custom portals typically have weaker auto-extraction than enterprise ATS platforms, and incomplete profiles can be filtered out.
  • For the French portal, use French accented characters correctly (é, è, à, ç) — incorrect encoding signals a hastily translated application.
  • Save your application confirmation email. Custom portals sometimes lack robust candidate dashboards, and the confirmation is your only proof of timely submission.
  • Do not apply to the same requisition twice within 30 days. Duplicate applications on small custom systems often trigger automatic rejection rather than updating the existing record.

Interview Culture

DBV's interview culture reflects its identity as a small, scientifically rigorous French biotech that has been through significant trauma.

Expect interviewers to be technically demanding, candid about the company's challenges, and genuinely interested in whether you understand what you would be signing up for. Conversations at the Châtillon HQ tend to follow French professional norms: more formal opening, vous as the default until invited otherwise, deeper credentialing on academic background (grandes écoles, doctorates, named labs), and a willingness to spend significant time on theoretical and methodological questions before moving to practical scenarios. US-based interviews in Basking Ridge are noticeably more direct and behavioral in style, with a heavier emphasis on cross-functional collaboration and execution under uncertainty. Across both geographies, candidates consistently report that the post-2024 DBV interview process is unusually transparent about the company's regulatory setbacks and financial position. Hiring managers will openly discuss the FDA Complete Response Letters, the workforce reduction, and the strategic review — and they expect candidates to have done their homework on the same topics. Vague enthusiasm without substantive engagement on these issues lands poorly. The strongest candidates ask specific, informed questions about the regulatory strategy under CEO Daniel Tassé, the cash runway, the prioritization of pipeline programs beyond Viaskin Peanut, and how the smaller post-restructuring organization is dividing responsibilities. Cultural fit at DBV in 2026 is less about polished corporate behaviors and more about whether you can operate calmly in a high-stakes turnaround context where every hire is scrutinized and every program decision matters.

What DBV Technologies Looks For

  • Genuine domain expertise in allergy, immunology, or related therapeutic areas — DBV cannot afford generalists in scientific or clinical roles, and superficial familiarity gets exposed quickly in technical interviews.
  • Regulatory submission experience with FDA, EMA, or PMDA — particularly Complete Response Letter remediation, IND/CTA amendments, and Type C/Pre-BLA meeting preparation given the company's specific regulatory history.
  • Comfort with ambiguity and a turnaround mindset — candidates who need stable headcount, clearly defined ladders, and predictable budgets will struggle in DBV's current operating environment.
  • Bilingual capability (French/English) for HQ roles, or strong cross-cultural collaboration skills for US and APAC-facing roles. The four-site footprint demands genuine global fluency.
  • Track record of doing more with less. Post-restructuring DBV is explicitly looking for hires who can own broader scopes than they would at a larger biotech, often spanning what would be 2-3 roles at a Sanofi or Pfizer.
  • Intellectual honesty about scientific and clinical risk — the company has been burned by overpromising, and leadership now prizes candidates who model their own work conservatively and surface bad news early.
  • Demonstrated resilience. Interviewers ask directly about how candidates have handled prior failures, layoffs, or program cancellations, and they evaluate the answers carefully.
  • Mission alignment with pediatric food allergy as an unmet need. Candidates who treat DBV as just another biotech job tend to disengage when the next setback hits; those with personal or professional connection to allergy patients tend to stay.

Frequently Asked Questions

Is DBV Technologies still hiring in 2026 after the 2024 layoffs?
Yes, but selectively. Following the approximately 70% workforce reduction in 2024, DBV has been hiring primarily for critical regulatory, clinical, and CMC roles tied to the Viaskin Peanut path forward, plus essential backfills. Expect open requisitions to be small in number, slow to close, and very specifically scoped — this is not a growth-mode biotech.
Do I need to speak French to work at DBV's Châtillon headquarters?
For most HQ roles, yes — practical working proficiency in French at C1 or above is effectively required. A small number of senior scientific or technical roles can be conducted primarily in English, but day-to-day collaboration, internal documentation, and meetings at Châtillon default to French. The Basking Ridge NJ office operates in English.
What happened with the FDA rejections of Viaskin Peanut?
The FDA issued Complete Response Letters in 2020 and again in 2024. The 2020 CRL focused on patch adhesion concerns and study design questions. The 2024 CRL followed additional clinical work and required further regulatory engagement. Combined with the 2024 ENABLE Phase 3 readout that did not meet primary endpoints cleanly, these setbacks triggered the strategic review and restructuring under new CEO Daniel Tassé.
Who is the CEO and what is the current strategy?
Daniel Tassé became CEO in March 2024 with a mandate to stabilize the company financially, refocus the pipeline, and engineer a credible regulatory path forward for Viaskin Peanut. The strategic review that began in 2024 has continued into 2025-2026, with ongoing decisions about pipeline prioritization, capital structure, and partnership opportunities.
How does DBV compare to competitors like Aimmune and Stallergenes Greer?
Nestlé Health Science's Palforzia (acquired from Aimmune) is an oral immunotherapy with FDA approval and commercial revenue, giving it significant resources and market presence. Stallergenes Greer has a broad allergy immunotherapy portfolio. DBV's differentiation is the epicutaneous patch delivery, which avoids oral dosing burdens but has faced its own regulatory challenges. DBV operates with materially less capital than these competitors.
What is compensation like at DBV Technologies?
Pay is competitive within the Paris biotech ecosystem at the Châtillon HQ — broadly in line with peer French biotechs but lower than US biotechs for equivalent roles. Basking Ridge NJ compensation is benchmarked to US pharma but tends to sit below large-cap biotech ranges. Equity is granted but its value depends entirely on a successful Viaskin Peanut path forward, given the share price volatility tied to regulatory and clinical outcomes.
What does DBV's office footprint look like?
Four sites: Châtillon (Île-de-France, southern Paris suburb) is the corporate and R&D headquarters; Basking Ridge, New Jersey hosts US operations including regulatory and commercial functions; Düsseldorf, Germany supports European activities; and Tokyo, Japan supports PMDA engagement and Asian regulatory strategy. Total headcount across all sites is approximately 150 as of 2026.
What is the interview process like at DBV?
Typically a recruiter screen, hiring manager interview, 2-3 functional interviews with peers and cross-functional stakeholders, and a final round with a department head or executive. Scientific and clinical roles include a technical presentation. Total process runs 6-10 weeks. Interviewers are notably transparent about the company's challenges and expect informed engagement on the regulatory and financial situation.
Should I be worried about job security at DBV?
Honest answer: yes, this is a real consideration. DBV is a clinical-stage biotech with no commercial revenue, two FDA setbacks, a recent major restructuring, and an ongoing strategic review. A second restructuring or significant pipeline change in the next 12-24 months is a non-trivial possibility. Candidates should weigh this against the meaningful scientific opportunity and ensure their personal financial runway can absorb the risk.
What kinds of roles are most commonly open at DBV in 2026?
Regulatory affairs (especially FDA-facing), clinical operations and clinical development, CMC and manufacturing for the patch platform, biostatistics and clinical pharmacology, and select R&D scientific roles tied to the immunotherapy platform. Commercial and corporate function hiring is minimal in the current operating posture.

Open Positions

DBV Technologies currently has 8 open positions.

Check Your Resume Before Applying → View 8 open positions at DBV Technologies

Related Resources

Similar Companies

Related Articles

Sources

  1. DBV Technologies Corporate Website — About Us — DBV Technologies SA
  2. DBV Technologies Careers Portal (France) — DBV Technologies SA
  3. DBV Technologies Receives Second Complete Response Letter from FDA for Viaskin Peanut — DBV Technologies SA Press Release
  4. DBV Technologies Announces Strategic Restructuring and Workforce Reduction — DBV Technologies SA Press Release
  5. Daniel Tassé Appointed Chief Executive Officer of DBV Technologies — DBV Technologies SA Press Release
  6. DBV Technologies SA (DBVT) NASDAQ Filings and Annual Report — U.S. Securities and Exchange Commission
  7. DBV Technologies (EPA:DBV) Document de Référence — Autorité des marchés financiers (AMF)
  8. Palforzia (Peanut Allergen Powder) Prescribing Information — U.S. Food and Drug Administration
  9. Epicutaneous Immunotherapy for Peanut Allergy: Clinical Development Overview — National Library of Medicine (PubMed)
  10. DBV Technologies Company Profile — LinkedIn